Dimensional Fund Advisors LP Sells 1,771,602 Shares of Roivant Sciences Ltd. $ROIV

Dimensional Fund Advisors LP cut its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 19.2% in the 1st quarter, HoldingsChannel.com reports. The firm owned 7,475,866 shares of the company’s stock after selling 1,771,602 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Roivant Sciences were worth $207,004,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ROIV. SBI Securities Co. Ltd. lifted its stake in Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after acquiring an additional 1,166 shares in the last quarter. Allworth Financial LP lifted its position in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares in the last quarter. Kestra Advisory Services LLC bought a new position in shares of Roivant Sciences during the fourth quarter valued at about $47,000. Parallel Advisors LLC boosted its holdings in Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after purchasing an additional 520 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its position in Roivant Sciences by 7,614.3% in the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after purchasing an additional 2,665 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insider Activity at Roivant Sciences

In other news, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total value of $6,632,000.00. Following the sale, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at $53,489,169.08. The trade was a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 12,380 shares of Roivant Sciences stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.28, for a total value of $436,766.40. Following the completion of the transaction, the director owned 13,689,166 shares of the company’s stock, valued at approximately $482,953,776.48. This trade represents a 0.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 1,855,913 shares of company stock worth $62,649,633. Company insiders own 10.80% of the company’s stock.

Roivant Sciences Trading Down 0.3%

Shares of NASDAQ ROIV opened at $35.01 on Friday. The stock has a fifty day simple moving average of $32.24 and a two-hundred day simple moving average of $28.62. Roivant Sciences Ltd. has a 1-year low of $10.90 and a 1-year high of $37.00. The firm has a market cap of $25.18 billion, a price-to-earnings ratio of -58.35 and a beta of 1.11.

Wall Street Analysts Forecast Growth

ROIV has been the topic of a number of research analyst reports. Guggenheim boosted their target price on Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Roivant Sciences in a research report on Thursday, May 21st. Leerink Partners set a $42.00 target price on Roivant Sciences in a research report on Thursday, May 21st. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Finally, TD Cowen increased their price target on shares of Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $33.59.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.